Rapport Therapeutics Inc.... (RAPP)

The healthcare industry has been a critical part of the economy for a long time. According to a McKinsey & Company report, the healthcare industry is expected to grow at 7% from 2022 to 2027.

Global markets are down as fears of an economic downturn triggered a near-term crisis. This is a reminder that corrections can come from most unexpected events.

Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.

Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.

Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their sh...

Rapport Therapeutics, Inc. has filed for a $100 million IPO to develop treatment candidates for central nervous system and related disorders. The company's lead candidate, RAP-219, is being developed ...